Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Intermittent Claudication-Pipeline Review, H1 2015

Intermittent Claudication-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Intermittent Claudication-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Intermittent Claudication-Pipeline Review, H1 2015', provides an overview of the Intermittent Claudication's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Intermittent Claudication, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intermittent Claudication and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Intermittent Claudication

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Intermittent Claudication and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Intermittent Claudication products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Intermittent Claudication pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Intermittent Claudication Overview 7

Therapeutics Development 8

Pipeline Products for Intermittent Claudication-Overview 8

Pipeline Products for Intermittent Claudication-Comparative Analysis 9

Intermittent Claudication-Therapeutics under Development by Companies 10

Intermittent Claudication-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Intermittent Claudication-Products under Development by Companies 13

Intermittent Claudication-Companies Involved in Therapeutics Development 14

Cytokinetics, Inc. 14

DNAVEC Corporation 15

Genovate Biotechnology Co., LTD. 16

Kowa Company, Ltd. 17

LTT Bio-Pharma Co., Ltd. 18

Nuo Therapeutics, Inc. 19

Pluristem Therapeutics Inc. 20

Rigel Pharmaceuticals, Inc. 21

Taisho Toyama Pharmaceutical Co., Ltd. 22

Intermittent Claudication-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

ALD-301-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

alprostadil-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

cilostazol CR-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

CK-2066260-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

DVC1-0101-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

ecraprost-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

K-134-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

LT-0101-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

R-118-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

tirasemtiv-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Intermittent Claudication-Recent Pipeline Updates 53

Intermittent Claudication-Dormant Projects 65

Intermittent Claudication-Discontinued Products 66

Intermittent Claudication-Product Development Milestones 67

Featured News & Press Releases 67

Mar 06, 2014: Rigel Announces Publication of R118 AMPK Activator Research 67

Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea 68

Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel 68

Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study 69

Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells 69

Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study 69

Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany 70

Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells 70

Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research 71

Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study 71

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 74

Disclaimer 74

List of Tables

Number of Products under Development for Intermittent Claudication, H1 2015 8

Number of Products under Development for Intermittent Claudication-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Intermittent Claudication-Pipeline by Cytokinetics, Inc., H1 2015 14

Intermittent Claudication-Pipeline by DNAVEC Corporation, H1 2015 15

Intermittent Claudication-Pipeline by Genovate Biotechnology Co., LTD., H1 2015 16

Intermittent Claudication-Pipeline by Kowa Company, Ltd., H1 2015 17

Intermittent Claudication-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 18

Intermittent Claudication-Pipeline by Nuo Therapeutics, Inc., H1 2015 19

Intermittent Claudication-Pipeline by Pluristem Therapeutics Inc., H1 2015 20

Intermittent Claudication-Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 21

Intermittent Claudication-Pipeline by Taisho Toyama Pharmaceutical Co., Ltd., H1 2015 22

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Stage and Target, H1 2015 25

Number of Products by Stage and Mechanism of Action, H1 2015 27

Number of Products by Stage and Route of Administration, H1 2015 29

Number of Products by Stage and Molecule Type, H1 2015 31

Intermittent Claudication Therapeutics-Recent Pipeline Updates, H1 2015 53

Intermittent Claudication-Dormant Projects, H1 2015 65

Intermittent Claudication-Discontinued Products, H1 2015 66

List of Figures

Number of Products under Development for Intermittent Claudication, H1 2015 8

Number of Products under Development for Intermittent Claudication-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Products, H1 2015 12

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Top 10 Targets, H1 2015 24

Number of Products by Stage and Top 10 Targets, H1 2015 25

Number of Products by Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Top 10 Routes of Administration, H1 2015 28

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29

Number of Products by Top 10 Molecule Types, H1 2015 30

Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Cytokinetics, Inc.

DNAVEC Corporation

Genovate Biotechnology Co., LTD.

Kowa Company, Ltd.

LTT Bio-Pharma Co., Ltd.

Nuo Therapeutics, Inc.

Pluristem Therapeutics Inc.

Rigel Pharmaceuticals, Inc.

Taisho Toyama Pharmaceutical Co., Ltd.

Intermittent Claudication Therapeutic Products under Development, Key Players in Intermittent Claudication Therapeutics, Intermittent Claudication Pipeline Overview, Intermittent Claudication Pipeline, Intermittent Claudication Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com